inhibitors can induce ARN. Herein, we report a patient who developed severe oligoanuric AKI shortly after initiation of treatment with apixaban (Eliquis, Bristol-Myers Squibb, New York, NY, USA) and provide kidney biopsy data supporting that the AKI was, at least mildly, associated with ARN.
Case report

Clinical history
The patient was an 82-year-old Caucasian female with history of hypertension, chronic obstructive pulmonary disease (COPD), coronary artery disease, congestive heart failure, and CKD stage III with baseline serum creatinine between 1.5 and 2.0 mg/dL. In 2013, she was found to have methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization. On March 9, 2017, she presented with symptoms of COPD exacerbation and AKI with a serum creatinine of 1.7 mg/dL. Her serum creatinine plateaued at a 3.26 mg/dL by March 13, 2017 (Fig.  1 ). She developed new-onset atrial fibrillation, for which treatment with apixaban (Eliquis) was initiated on March 15, 2017. The dose of apixaban was 2.5 mg (per oral, twice a day), based on her age over 80 and creatinine over 1.5 mg/dL.
The patient had a CHAD2-VASC score of 6, and rate control was achieved. The plan was to cardiovert in 3 to 4 weeks, but she spontaneously converted to normal sinus rhythm during that time. Based on her echocardiogram performed on March 31, 2017, non-valvular atrial fibrillation was diagnosed (only mild mitral regurgitation reported).
Serum creatinine was 3.5 mg/dL on March 25, 2017, and she was noted to have 1.1 g of proteinuria on a spot urine protein: creatinine ratio. She presented on March 25, 2017 with oligoanuria and serum creatinine of 8.52 mg/dL; hemodialysis was initiated.
The patient did not exhibit any symptoms or adverse effects that were attributable to apixaban, such as overt hemorrhage. For this reason, Factor Xa level was not tested. However, a urinalysis did reveal microscopic hematuria in the setting of a Foley catheter.
Urinalysis at the time of this presentation showed a large amount of blood, with 20-50 RBCs per high power field, which was not apparent two months prior (Fig. 1) . She was found to be positive for p-ANCA (perinuclear anti-neutrophil cytoplasmic antibodies; subsequent testing of antibody to myeloperoxidase [MPO] was negative at < 0.2), whereas cytoplasmic ANCA (c-ANCA), antinuclear antibody (ANA), and anti-glomerular basement membrane (GBM) antibodies were negative, as was her hepatitis profile. Serum complement levels and rheumatoid factor were normal. During her first admission, she was given steroids for COPD exacerbation. During the second admission, she received three doses of methylprednisolone (Solu-Medrol) 500 mg/day starting on March 26, 2017 for suspected ANCA-related vasculitis. Three sets of blood cultures drawn over both admissions were all negative, and transthoracic echocardiogram was negative for vegetation. The patient remained afebrile throughout both admissions. A kidney biopsy was performed on April 3, 2017 after apixaban was stopped; however, she did receive subcutaneous heparin. Unfortunately, the patient remains dialysis dependent as of August 2017.
Pathologic findings
The kidney biopsy specimen contained 7 cores of renal parenchyma. Tissue submitted for light microscopy con- www.krcp-ksn.org tained an ample amount of renal cortex. Paraffin sections were stained with hematoxylin and eosin, periodic acidSchiff (PAS), PAS-trichrome [9] , and methenamine silver stains. Up to 157 glomeruli per section were identified by light microscopy. At least 107 of these glomeruli were obsolescent and localized to the areas of renal cortical scarring. Distant from the scar tissue, there were 50 glomeruli, and up to 22 of them were obsolescent, scattered throughout the non-scarred renal cortex. In one glomerulus, a small segmental cellular crescent was noted ( Fig.  2A) . In three additional glomeruli, small segmental areas of necrosis were present without associated cellular crescents. gial staining for immunoglobulin A (IgA) and kappa and lambda light chains was seen in the glomeruli (Fig. 3A, B) . All other stains were negative in the glomeruli. Semi-thin sections of the tissue submitted for electron microscopy contained renal cortex with one light microscopically unremarkable glomerulus. Ultrastructurally, scattered small mesangial and intramembranous electron-dense deposits were identified (Fig. 3C) . The GBM was of normal thickness and texture. Podocyte foot process effacement was mild. No endothelial tubuloreticular inclusions were identified. Dysmorphic RBCs were seen in Bowman's space (Fig. 3D) .
The etiology of this chronic kidney injury is difficult to determine based on kidney biopsy findings alone. Globally sclerosed glomeruli did not show obvious fibrous crescents; therefore, they are probably not related to crescentic glomerulonephritis. Because of the somewhat zonal renal cortical scarring, it is possible that this chronic kidney injury is of the vascular origin and might be related to antiphospholipid antibodies, preeclampsia, or other vasculopathies. Chronic pyelonephritis/reflux nephropathy is also a consideration, but this diagnosis could not be made based on the kidney biopsy findings alone. It is difficult to differentiate between IgA nephropathy and infection-related glomerulonephritis based on kidney biopsy findings. However, the absence of hematu- www.krcp-ksn.org ria history favors infection-associated glomerulonephritis.
Discussion
To the best of our knowledge, this is the first case report of AKI associated with treatment with a Factor Xa inhibitor. We and others previously reported several cases of AKI associated with warfarin or dabigatran [3] [4] [5] 10, 11] .
The clinical history and kidney biopsy findings in this patient strongly indicate that an oligoanuric AKI can be associated with anticoagulation therapy. Clinically, serum creatinine was increased from baseline before the initiation of anticoagulation in the present patient, but it was plateauing. After starting apixaban, serum creatinine significantly increased (from 3.2 to 8.5 mg/dL) within a few days, and the patient became oligoanuric. This was associated with new hematuria. All of these clinical symptoms have been seen in patients with WRN or dabigatran-associated AKI. Pathologic findings showed significant discrepancy between the number of tubular RBC casts and the degree of glomerular injury. The most striking biopsy finding was prominent glomerular hematuria, and the occlusive RBC casts likely contributed to the oligoanuric AKI. Even though patient had positive p-ANCA, a subsequent test for MPO antibody was negative. There was only one cellular crescent in the entire biopsy specimen with at least 68 non-sclerotic glomeruli, and only three glomeruli showed small areas of segmental necrosis. Therefore, there is a major discrepancy between the degree of AKI, the degree of acute tubular necrosis with occlusive RBC casts, and the subtle crescentic and necrotizing glomerular changes. The presence of mild, mainly mesangial IgA-and C3-containing immune complex deposition is also unusual in ANCA-associated glomerulonephritis. In our experience, focal crescentic glomerulonephritis can be associated with infection, including endocarditis [12] . The pattern of C3-dominant glomerular immune complex deposits raises the possibility of an underlying staphylococcus infection, in spite of negative blood cultures. It is of interest that this patient was found to have nasal colonization of MRSA in 2013. Also, ANCA can be positive in 20-30% of patients with infectionassociated glomerulonephritis [12] . The rapid decline in kidney function with oligoanuria developed after starting anticoagulation with apixaban; therefore, we believe that anticoagulation aggravated preexisting kidney injury and resulted in severe glomerular hemorrhage with occlusive RBC casts and ATN, which are features of ARN. One of the possible etiologies for this ARN is preexisting AKI; because renal excretion accounts for about 27% of the total clearance of apixaban [13] , it is possible that there was an overdose of apixaban associated with reduced elimination of the drug. However, even without the overdose, anticoagulation might have increased glomerular hematuria in this patient with very focal segmental and necrotizing glomerulonephritis and mild mesangial immune complex deposits.
There is growing evidence that ARN is a potentially serious complication of anticoagulation therapy. In addition to warfarin, there are several recent case reports that AKI with hematuria and RBC tubular casts can develop in patients on dabigatran treatment [4, 11] . The most rigorous attempt to understand the renal risks of warfarin versus DOAC was the recent retrospective analysis of RE-LY [8] . That analysis showed substantial glomerular filtration rate (eGFR) loss during follow up in both the warfarin and dabigatran cohorts, at about 2-3 mL/min/year. This is two to three times greater than the expected eGFR decline attributable to aging (1 mL/min/year) [14] .
In conclusion, we present the first documented by kidney biopsy evidence that patients on anticoagulation treatment with Factor Xa inhibitor can develop glomerular hematuria and AKI. In this particular patient, there was a constellation of other factors that probably was responsible for this AKI; nevertheless, this is a confirmation that another class of DOAC can induce AKI in susceptible patients. We suggest that kidney function should be closely monitored in all CKD patients after initiation of anticoagulation therapy.
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